Completed PHASE1 INTERVENTIONAL 1-arm NCT02793960

Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Therapeutic Effect of Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa

Sponsor: BPGbio

Conditions Epidermolysis Bullosa

Interventions topical BPM31510 3.0% Cream

Updated 11 times since 2017 Last updated: Jun 14, 2020 Started: Aug 10, 2016 Primary completion: Aug 26, 2019 Completion: Aug 26, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Epidermolysis Bullosa and is currently completed. BPGbio leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jul 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Feb 2020 — Jul 2020 [monthly]

Active Not Recruiting PHASE1

▶ Show 6 earlier versions

Aug 2019 — Feb 2020 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2019 — Aug 2019 [monthly]

Recruiting PHASE1
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE1
Jun 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BPGbio
Shasa Hu

Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States